Sherry Korczynski net worth and biography

Sherry Korczynski Biography and Net Worth

Sherry Korczynski joined Aquestive in February 2024 to oversee marketing. Prior to joining Aquestive, Ms. Korczynski served in multiple sales and marketing leadership roles at ANI Pharmaceuticals, Eagle Pharmaceuticals, Mylan Pharmaceuticals (now Viatris), and Eli Lilly and Company. She has significant experience in the allergy therapeutic area, leading marketing, public relations, and advocacy for the EpiPen® brand. Ms. Korczynski received her B.S. in Marketing from The Pennsylvania State University and an M.B.A. from West Virginia University.

What is Sherry Korczynski's net worth?: The estimated net worth of Sherry Korczynski is at least $935.53 thousand as of March 10th, 2026. Korczynski owns 241,117 shares of Aquestive Therapeutics stock worth more than $935,534 as of March 24th. This net worth estimate does not reflect any other assets that Korczynski may own. Learn More about Sherry Korczynski's net worth.
How do I contact Sherry Korczynski?: The corporate mailing address for Korczynski and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Sherry Korczynski's contact information.
Has Sherry Korczynski been buying or selling shares of Aquestive Therapeutics?: Within the last three months, Sherry Korczynski has sold $65,639.97 of Aquestive Therapeutics stock. Most recently, Sherry Korczynski sold 15,741 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a transaction totalling $65,639.97. Following the completion of the sale, the insider now directly owns 241,117 shares of the company's stock, valued at $1,005,457.89. Learn More on Sherry Korczynski's trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Daniel Barber (CEO), Peter Boyd (Insider), Lori Braender (Insider), Melina Cioffi (SVP), Ernest Jr (CFO), Cassie Jung (COO), Sherry Korczynski (Insider), Carl Kraus (Insider), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 3/10/2026.

Sherry Korczynski Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2026	Sell	15,741	$4.17	$65,639.97	241,117

Sherry Korczynski Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $3.88

$3.77

$3.91

50 Day Range

MA: $3.83

$2.95

$4.37

2 Week Range

Now: $3.88

$2.12

$7.55

Volume

1,537,372 shs

Average Volume

5,024,399 shs

Market Capitalization

$473.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61